Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Bristol-Myers Squibb Co., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Short-term debt obligations	3,554)	2,046)	1,078)	3,531)	6,190)	3,119)	5,467)	3,020)	2,752)	4,264)	2,132)	4,953)	7,522)	4,948)	5,065)	2,655)	1,777)	2,340)	3,585)	4,819)	3,862)
Accounts payable	4,002)	3,602)	3,469)	3,751)	3,539)	3,259)	2,813)	3,069)	3,194)	3,040)	2,595)	2,882)	2,944)	2,949)	2,695)	3,609)	2,972)	2,713)	2,441)	2,852)	3,069)
Other current liabilities	16,514)	18,126)	18,091)	15,983)	16,093)	15,884)	15,182)	14,061)	13,139)	14,586)	14,203)	13,080)	12,355)	13,971)	13,700)	12,727)	12,581)	14,027)	14,438)	15,750)	12,301)
Current liabilities	24,070)	23,774)	22,638)	23,265)	25,822)	22,262)	23,462)	20,150)	19,085)	21,890)	18,930)	20,915)	22,821)	21,868)	21,460)	18,991)	17,330)	19,080)	20,464)	23,421)	19,232)
Deferred income taxes	276)	369)	430)	461)	442)	338)	399)	751)	1,568)	2,166)	2,881)	3,034)	3,809)	4,501)	4,956)	4,931)	5,235)	5,407)	5,913)	6,157)	6,531)
Long-term debt, excluding current portion	46,157)	47,603)	48,674)	48,858)	49,487)	36,653)	32,137)	34,656)	35,078)	35,056)	36,966)	37,107)	37,450)	39,605)	39,677)	42,503)	44,505)	48,336)	41,364)	41,853)	42,844)
Other non-current liabilities	4,476)	4,469)	4,728)	4,993)	6,732)	6,421)	6,203)	5,902)	6,664)	6,590)	6,685)	6,640)	7,309)	7,334)	7,516)	7,498)	7,692)	7,776)	7,565)	7,485)	10,701)
Non-current liabilities	50,909)	52,441)	53,832)	54,312)	56,661)	43,412)	38,739)	41,309)	43,310)	43,812)	46,532)	46,781)	48,568)	51,440)	52,149)	54,932)	57,432)	61,519)	54,842)	55,495)	60,076)
Total liabilities	74,979)	76,215)	76,470)	77,577)	82,483)	65,674)	62,201)	61,459)	62,395)	65,702)	65,462)	67,696)	71,389)	73,308)	73,609)	73,923)	74,762)	80,599)	75,306)	78,916)	79,308)
Preferred stock	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Common stock	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)	292)
Capital in excess of par value of stock	46,012)	46,024)	45,896)	45,766)	45,655)	45,684)	44,849)	45,299)	45,140)	45,165)	44,956)	44,375)	43,756)	44,361)	44,292)	44,064)	43,852)	44,325)	44,435)	44,444)	43,254)
Accumulated other comprehensive loss	(1,424)	(1,238)	(1,468)	(1,456)	(1,400)	(1,546)	(1,286)	(1,387)	(1,368)	(1,281)	(841)	(992)	(1,229)	(1,268)	(1,424)	(1,518)	(1,544)	(1,839)	(1,699)	(1,556)	(1,549)
Retained earnings	16,106)	14,912)	16,097)	16,103)	15,640)	28,766)	28,218)	27,449)	26,568)	25,503)	24,675)	24,217)	23,948)	23,820)	22,625)	22,168)	22,204)	21,281)	32,414)	31,565)	32,671)
Cost of treasury stock	(43,597)	(43,655)	(43,675)	(43,690)	(43,697)	(43,766)	(43,075)	(39,680)	(38,808)	(38,618)	(36,411)	(35,292)	(35,187)	(31,259)	(28,572)	(28,198)	(27,199)	(26,237)	(25,284)	(25,651)	(24,757)
Total BMS shareholders’ equity	17,389)	16,335)	17,142)	17,015)	16,490)	29,430)	28,998)	31,973)	31,824)	31,061)	32,671)	32,600)	31,580)	35,946)	37,213)	36,808)	37,605)	37,822)	50,158)	49,094)	49,911)
Noncontrolling interest	59)	53)	58)	54)	58)	55)	64)	57)	62)	57)	63)	61)	65)	60)	71)	66)	68)	60)	72)	66)	66)
Total equity	17,448)	16,388)	17,200)	17,069)	16,548)	29,485)	29,062)	32,030)	31,886)	31,118)	32,734)	32,661)	31,645)	36,006)	37,284)	36,874)	37,673)	37,882)	50,230)	49,160)	49,977)
Total liabilities and equity	92,427)	92,603)	93,670)	94,646)	99,031)	95,159)	91,263)	93,489)	94,281)	96,820)	98,196)	100,357)	103,034)	109,314)	110,893)	110,797)	112,435)	118,481)	125,536)	128,076)	129,285)

Short-term debt obligations: Short-term debt displayed considerable fluctuations throughout the observed period. Starting at $3,862 million in Q1 2020, it surged to a peak of $7,522 million in Q1 2022 before declining significantly to $1,078 million in Q3 2024. This volatility suggests active management of short-term financing needs.
Accounts payable: Accounts payable remained relatively stable with mild fluctuations around the $3,000 million mark. A slight increasing trend is observed towards the end of the series, reaching approximately $4,002 million by Q1 2025, indicating a gradual rise in company payables.
Other current liabilities: Other current liabilities showed variability, peaking near $18,126 million in Q4 2024 after an overall upward trajectory from $12,301 million in Q1 2020. This reflects a growing portion of current obligations outside of payables and short-term debt.
Current liabilities: Current liabilities in total demonstrated volatility but with a moderate upward movement, ranging from $19,232 million in Q1 2020 to $24,070 million in Q1 2025, suggesting an increase in liabilities due within a year, driven largely by other current liabilities and short-term debt changes.
Deferred income taxes: Deferred income taxes consistently declined over the period, dropping from $6,531 million in Q1 2020 to $276 million by Q1 2025. This steady decrease signals a reduction in deferred tax liabilities or changes in tax strategy or asset valuations affecting deferred taxes.
Long-term debt, excluding current portion: Long-term debt decreased from $42,844 million in Q1 2020 to $32,137 million by Q4 2021 but showed a rebound thereafter, reaching $49,487 million in Q2 2024 before a slight decrease to $46,157 million in Q1 2025. This pattern indicates episodic borrowings or refinancings over the period.
Other non-current liabilities: Other non-current liabilities decreased overall from $10,701 million in Q1 2020 to around $4,476 million in Q1 2025, suggesting repayments or reductions in long-term non-debt obligations.
Non-current liabilities: Non-current liabilities diminished from $60,076 million in Q1 2020 to $38,739 million by Q4 2021, followed by an increase peaking at $56,661 million in Q2 2024 before stabilizing around $50,909 million in Q1 2025. This reflects underlying changes in long-term financing and obligations.
Total liabilities: Total liabilities followed a somewhat downward trend from $79,308 million in Q1 2020 to approximately $62,395 million in Q1 2023, but rose again to $82,483 million by Q2 2024 before easing to $74,979 million in Q1 2025. This suggests changing leverage and liability management.
Equity components: Common stock remained constant at $292 million throughout. Capital in excess of par value showed a gradual increase from $43,254 million to around $46,012 million, indicating additional paid-in capital growth. Accumulated other comprehensive loss fluctuated but stayed negative, generally near -$1,400 million, exposing some losses from comprehensive income items.
Retained earnings: Retained earnings initially rose from $32,671 million in Q1 2020 to a peak near $28,766 million in Q4 2022 but then dramatically declined to approximately $14,912 million in Q1 2025, indicating either significant losses or distributions offsetting accumulated earnings.
Cost of treasury stock: The cost of treasury stock steadily increased in absolute value (more negative), starting at -$24,757 million and reaching a level near -$43,597 million by Q1 2025, which signals ongoing stock repurchases or treasury shares accumulation.
Total shareholders’ equity and total equity: Total shareholders’ equity dropped from $49,911 million in Q1 2020 to a low of about $16,490 million in Q1 2024 before a slight recovery, ending near $17,389 million in Q1 2025. Total equity mirrored this pattern, declining sharply and modestly recovering. This decline contrasts with stable or growing liabilities, suggesting challenges in equity value maintenance.
Total liabilities and equity: The sum of liabilities and equity decreased steadily from $129,285 million in Q1 2020 to approximately $92,427 million in Q1 2025, indicating a reduction in overall company capitalization and liabilities, possibly due to asset sales, restructuring, or other strategic financial decisions.

Download chart

Bristol-Myers Squibb Co. (NYSE:BMY)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data